CorMedix, Inc. (CRMD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Poseida Therapeutics, Inc.

Xeris Biopharma Holdings, Inc.

Monte Rosa Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Akoya Biosciences, Inc.

Verastem, Inc.

ProKidney Corp.

AlloVir, Inc.

Reneo Pharmaceuticals, Inc.

Synlogic, Inc.

Why is CorMedix, Inc. ?

With a growth in Net Sales of 1.68%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 3 consecutive quarters
PRE-TAX PROFIT(Q) At USD 20.35 MM has Grown at 373.79%
NET PROFIT(Q) At USD 19.83 MM has Grown at 361.65%
OPERATING CASH FLOW(Y) Highest at USD 30.47 MM

With ROE of 14.95%, it has a expensive valuation with a 8.25 Price to Book Value

Over the past year, while the stock has generated a return of -5.53%, its profits have risen by 134.2% ; the PEG ratio of the company is 0.4

High Institutional Holdings at 51.74%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 3.79% over the previous quarter.

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to CorMedix, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is CorMedix, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

CorMedix, Inc.

8.02%

0.77

81.64%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

161.51%

EBIT Growth (5y)

31.73%

EBIT to Interest (avg)

-25.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.67

Sales to Capital Employed (avg)

0.25

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

51.74%

ROCE (avg)

7.71%

ROE (avg)

2.99%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.25

EV to EBIT

60.17

EV to EBITDA

57.92

EV to Capital Employed

23.19

EV to Sales

10.55

PEG Ratio

0.42

Dividend Yield

ROCE (Latest)

38.54%

ROE (Latest)

14.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

35What is working for the Company

PRE-TAX PROFIT(Q)

At USD 20.35 MM has Grown at 373.79%

NET PROFIT(Q)

At USD 19.83 MM has Grown at 361.65%

OPERATING CASH FLOW(Y)

Highest at USD 30.47 MM

NET SALES(HY)

Higher at USD 78.82 MM

ROCE(HY)

Highest at 38.35%

RAW MATERIAL COST(Y)

Fallen by -163.8% (YoY

CASH AND EQV(HY)

Highest at USD 268.21 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 5.57 times

-5What is not working for the Company

INTEREST(9M)

At USD 0.03 MM has Grown at 62.8%

Here's what is working for CorMedix, Inc.

Net Sales

At USD 78.82 MM has Grown at 9,677.52%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 20.35 MM has Grown at 373.79%

over average net sales of the previous four periods of USD 4.3 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 19.83 MM has Grown at 361.65%

over average net sales of the previous four periods of USD 4.3 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Higher at USD 78.82 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Operating Cash Flow

Highest at USD 30.47 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 268.21 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 5.57 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -163.8% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CorMedix, Inc.

Interest

At USD 0.03 MM has Grown at 62.8%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)